218 related articles for article (PubMed ID: 25259743)
21. Paricalcitol for secondary hyperparathyroidism in renal transplantation.
Trillini M; Cortinovis M; Ruggenenti P; Reyes Loaeza J; Courville K; Ferrer-Siles C; Prandini S; Gaspari F; Cannata A; Villa A; Perna A; Gotti E; Caruso MR; Martinetti D; Remuzzi G; Perico N
J Am Soc Nephrol; 2015 May; 26(5):1205-14. PubMed ID: 25194004
[TBL] [Abstract][Full Text] [Related]
22. A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria.
Susantitaphong P; Nakwan S; Peerapornratana S; Tiranathanagul K; Katavetin P; Srisawat N; Praditpornsilpa K; Eiam-Ong S
BMC Nephrol; 2017 Jan; 18(1):19. PubMed ID: 28088187
[TBL] [Abstract][Full Text] [Related]
23. Proteinuria and Albuminuria During and After Paricalcitol Treatment in Chronic Kidney Disease Patients.
Ekart R; Bevc S; Hojs R; Hojs N
J Clin Pharmacol; 2016 Jun; 56(6):761-8. PubMed ID: 26465921
[TBL] [Abstract][Full Text] [Related]
24. Paricalcitol regulatory effect on inflammatory, fibrotic and anticalcificating parameters in renal patiente. Far beyond mineral bone disease regulation.
Salanova Villanueva L; Gil Giraldo Y; Santos Sánchez-Rey B; Aguilera Peralta A
Nefrologia (Engl Ed); 2020; 40(2):171-179. PubMed ID: 31740151
[TBL] [Abstract][Full Text] [Related]
25. Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability.
Vila Cuenca M; Ferrantelli E; Meinster E; Pouw SM; Kovačević I; de Menezes RX; Niessen HW; Beelen RHJ; Hordijk PL; Vervloet MG
J Am Heart Assoc; 2018 Sep; 7(17):e008776. PubMed ID: 30371149
[TBL] [Abstract][Full Text] [Related]
26. Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial.
Kendrick J; Andrews E; You Z; Moreau K; Nowak KL; Farmer-Bailey H; Seals DR; Chonchol M
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1438-1446. PubMed ID: 28784657
[TBL] [Abstract][Full Text] [Related]
27. Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease.
de Boer IH; Sachs M; Hoofnagle AN; Utzschneider KM; Kahn SE; Kestenbaum B; Himmelfarb J
Kidney Int; 2013 Feb; 83(2):323-30. PubMed ID: 22913981
[TBL] [Abstract][Full Text] [Related]
28. Endothelium-Dependent and -Independent Vascular Function in Advanced Chronic Kidney Disease.
Kopel T; Kaufman JS; Hamburg N; Sampalis JS; Vita JA; Dember LM
Clin J Am Soc Nephrol; 2017 Oct; 12(10):1588-1594. PubMed ID: 28784655
[TBL] [Abstract][Full Text] [Related]
29. Paricalcitol reduces proteinuria in non-dialysis chronic kidney disease patients.
Hojs N; Bevc S; Balon BP; Hojs R; Ekart R
Ther Apher Dial; 2013 Aug; 17(4):368-72. PubMed ID: 23931873
[TBL] [Abstract][Full Text] [Related]
30. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease.
Tamez H; Zoccali C; Packham D; Wenger J; Bhan I; Appelbaum E; Pritchett Y; Chang Y; Agarwal R; Wanner C; Lloyd-Jones D; Cannata J; Thompson BT; Andress D; Zhang W; Singh B; Zehnder D; Pachika A; Manning WJ; Shah A; Solomon SD; Thadhani R
Am Heart J; 2012 Dec; 164(6):902-9.e2. PubMed ID: 23194491
[TBL] [Abstract][Full Text] [Related]
31. Effects of paricalcitol on urinary calcium in patients with chronic kidney disease stages 2 - 4.
Martinez-Fernandez I; Saracho R
Clin Nephrol; 2015 Apr; 83(4):201-7. PubMed ID: 25707454
[TBL] [Abstract][Full Text] [Related]
32. Paricalcitol versus placebo for reduction of proteinuria in kidney transplant recipients: a double-blind, randomized controlled trial.
Oblak M; Mlinšek G; Kandus A; Buturović-Ponikvar J; Arnol M
Transpl Int; 2018 Dec; 31(12):1391-1404. PubMed ID: 30062716
[TBL] [Abstract][Full Text] [Related]
33. Changes in microparticle profiles by vitamin D receptor activation in chronic kidney disease - a randomized trial.
Lundwall K; Mörtberg J; Mobarrez F; Jacobson SH; Jörneskog G; Spaak J
BMC Nephrol; 2019 Aug; 20(1):290. PubMed ID: 31370809
[TBL] [Abstract][Full Text] [Related]
34. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
Kovesdy CP; Lu JL; Malakauskas SM; Andress DL; Kalantar-Zadeh K; Ahmadzadeh S
Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174
[TBL] [Abstract][Full Text] [Related]
35. A randomised clinical study of alfacalcidol and paricalcitol.
Hansen D
Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
[TBL] [Abstract][Full Text] [Related]
36. Vitamin D receptor activation reduces inflammatory cytokines and plasma MicroRNAs in moderate chronic kidney disease - a randomized trial.
Mansouri L; Lundwall K; Moshfegh A; Jacobson SH; Lundahl J; Spaak J
BMC Nephrol; 2017 May; 18(1):161. PubMed ID: 28511692
[TBL] [Abstract][Full Text] [Related]
37. Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial.
Riccio E; Sabbatini M; Bruzzese D; Capuano I; Migliaccio S; Andreucci M; Pisani A
PLoS One; 2015; 10(3):e0118174. PubMed ID: 25781618
[TBL] [Abstract][Full Text] [Related]
38. Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial.
Joergensen C; Tarnow L; Goetze JP; Rossing P
Diabet Med; 2015 Mar; 32(3):374-81. PubMed ID: 25307511
[TBL] [Abstract][Full Text] [Related]
39. Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease : A meta-analysis.
Hu X; Shang J; Yuan W; Zhang S; Jiang Y; Zhao B; Duan Y; Xiao J; Zhao Z
Herz; 2018 Sep; 43(6):518-528. PubMed ID: 28835982
[TBL] [Abstract][Full Text] [Related]
40. Clinical trials: cardiovascular benefits of paricalcitol in chronic kidney disease.
Edwards JK
Nat Rev Nephrol; 2014 Dec; 10(12):675. PubMed ID: 25347944
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
